Physician profile
Ronald E Pruitt
NPI 1770582140
$14,203.90
in general payments reported to CMS, 2019-2025
43 companies · $134 in 2025
The $134 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,425 · 2020: $1,794 · 2021: $2,681 · 2022: $2,943 · 2023: $2,321 · 2024: $1,907 · 2025: $134.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,323 · Education: $38.97.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,323.04 |
| Education | $38.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $3,990.66 | 2019-2024 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,957.35 | 2019-2024 | Xifaxan, Trulance |
| Gilead Sciences, INC. | $1,942.23 | 2019-2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $1,339.85 | 2019-2024 | Entyvio, Eohilia |
| Janssen Biotech, INC. | $638.87 | 2019-2024 | Stelara, Simponi Aria, Simponi |
| Qol Medical, LLC | $586.70 | 2019-2024 | Sucraid, Sucraid |
| Intercept Pharmaceuticals, INC. | $508.75 | 2019-2024 | Ocaliva |
| Pfizer INC. | $318.57 | 2019-2024 | |
| Ironwood Pharmaceuticals, INC | $317.26 | 2019-2023 | Linzess |
| Genzyme Corporation | $257.15 | 2022-2024 | |
| Merck Sharp & Dohme LLC | $198.38 | 2019-2023 | Dificid |
| Daiichi Sankyo INC. | $197.95 | 2019-2022 | |
| Nestle Healthcare Nutrition INC. | $179.89 | 2021-2023 | |
| Ferring Pharmaceuticals INC. | $159.29 | 2020-2023 | Rebyota |
| Conmed Corporation | $156.79 | 2022-2024 | Conmed Biliary |
Show all 42 companies
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ronald Pruitt listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.